Acrivon Therapeutics (NASDAQ:ACRV) Research Coverage Started at Cantor Fitzgerald

Cantor Fitzgerald started coverage on shares of Acrivon Therapeutics (NASDAQ:ACRV) in a report released on Friday,Benzinga reports. The firm issued an overweight rating on the stock.

Several other analysts have also recently commented on ACRV. KeyCorp began coverage on shares of Acrivon Therapeutics in a research note on Friday. They issued an “overweight” rating for the company. BMO Capital Markets lowered their price objective on Acrivon Therapeutics from $28.00 to $27.00 and set an “outperform” rating on the stock in a report on Thursday, November 14th. Finally, HC Wainwright reissued a “buy” rating and set a $22.00 target price on shares of Acrivon Therapeutics in a research note on Thursday, November 14th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $23.67.

Acrivon Therapeutics Stock Up 4.8 %

ACRV opened at $6.07 on Friday. The firm has a market cap of $189.02 million, a price-to-earnings ratio of -2.25 and a beta of 0.77. Acrivon Therapeutics has a 52 week low of $3.19 and a 52 week high of $11.90. The business’s 50 day moving average is $6.34 and its two-hundred day moving average is $7.33.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Exome Asset Management LLC purchased a new position in Acrivon Therapeutics in the 3rd quarter worth approximately $817,000. State Street Corp boosted its stake in shares of Acrivon Therapeutics by 26.4% in the third quarter. State Street Corp now owns 225,896 shares of the company’s stock valued at $1,581,000 after purchasing an additional 47,233 shares during the period. JPMorgan Chase & Co. grew its holdings in Acrivon Therapeutics by 548.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 33,991 shares of the company’s stock valued at $238,000 after purchasing an additional 28,748 shares in the last quarter. Barclays PLC increased its stake in Acrivon Therapeutics by 51.2% during the 3rd quarter. Barclays PLC now owns 33,306 shares of the company’s stock worth $233,000 after buying an additional 11,273 shares during the period. Finally, Dimensional Fund Advisors LP acquired a new position in Acrivon Therapeutics in the 2nd quarter worth $58,000. 71.62% of the stock is owned by institutional investors and hedge funds.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.